Article by:
Shawn Radcliffe
Biopharma company Viking Therapeutics released promising initial results on Feb. 27 from a mid-stage clinical trial for its experimental weight loss drug.
The phase 2 trial followed 176 adults who were obese or overweight. Researchers randomly assigned people to receive one of four doses of the test drug, VK2734, or an inactive placebo. Read the full article...
Google